ArticleFrontiers in neurology2025
Correlation study between serum uric acid level and cognitive impairment in middle-aged and elderly patients with hypertension: based on an explainable predictive model.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with primary hypertension are always comorbid with hyperuricemia. Serum uric acid exhibits a dual role in cognitive function. Evidence regarding the relationship between uric acid (SUA) and cognitive dysfunction in specific hypertensive patients remains inconsistent. Objective: To develop a predictive model to evaluate the association between serum uric acid level and mild cognitive impairment (MCI) in hypertensive populations. Methods: This cross-sectional study involved 420 middle-aged and elderly hypertensive patients. Cognitive function was evaluated using MMSE and MoCA. Univariate and multivariate logistic regression, restricted cubic splines (RCS), and SHAP analysis were employed. Results: In MCI group, diabetes prevalence, hyperuricemia prevalence, arteriosclerosis prevalence, education level, MMSE score, MoCA score, AD8 score and HbA1c were higher, while weight, BMI, SUA, TC, LDL, Alb, TT3, TSH, and FT3 were lower. After adjusting for confounding factors, it was found that the SUA level (OR = 0.754, 95%CI: 0.578-0.985, 0.038) could still be used as an independent protective factor for MCI. Subgroup analyses indicated effects varied significantly with diabetes history and regular exercise. Shap values showed that SUA is the fifth most related factor, with more significant ones including age, education level, albumin and thyroxin. A nonlinear association was found between SUA and MCI risk, with an inflection point at approximately 450 μmol/L. Conclusion: SUA has a certain correlation with MCI in the middle-aged and elderly hypertensive populations. Although SUA is considered as a neuroprotective agent, its neuroprotective function gradually diminishes and may even become detrimental when SUA higher than a threshold. These results suggest maintaining SUA within an optimal range may help mitigate MCI risk in hypertensive populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.